Key Points Great dividend payers can support and raise their payouts through the years. VICI Properties is a leading REIT with a vast portfolio of experience-oriented properties. Bristol Myers Squibb is a top pharmaceutical business with a vast portfolio of profitable drugs. 10 stocks we like better than Vici Properties › Adding dividend stocks to your portfolio can provide a steady source of income and help buffer portfolio losses during market downturns. However, it's important to carefully re ...

Core Insights - Axsome Therapeutics Inc's stock is experiencing significant gains, rising 19% to $177.13 after the FDA granted priority review for its Alzheimer's disease agitation drug AXS-05 [1] - Analysts from Needham and TD Cowen have reiterated "buy" ratings, with Needham increasing its price target from $154 to $169 [1] - The stock is on track for its largest single-day percentage gain since February, reaching a record peak of $178.99 [2] Stock Performance - If current gains are maintained, Axsome Therapeutics is projected to finish 2025 with over 100% year-to-date gain [2] - The options market has seen a surge, with AXSM's options volume reaching ten times its average daily volume, particularly in the January 2026 185-strike call [2] Short Interest - A portion of the stock's increase may be due to short covering, as short interest accounts for 6.8% of the stock's available float [3] - It would take over five days for short sellers to buy back their borrowed shares based on the stock's average trading pace [3]

Key Points Eli Lilly is working on the acquisition of a France-based drugmaker. This could allow it to expand its footprint in the immunology market. There are plenty of reasons to like the stock beyond this development. 10 stocks we like better than Eli Lilly › Everything seems to be going well for Eli Lilly (NYSE: LLY). The company's shares have soared in recent years thanks to strong clinical progress within its GLP-1 franchise. The drugmaker has established itself as a leader in the fast-gr ...

Company Overview - International Isotopes Inc. has officially changed its name to Radnostix, Inc. to better reflect its evolving focus on radioisotopes and theranostics products [1][3] - The company was established in 1995 and is headquartered in Idaho Falls, ID, USA, specializing in the manufacturing of a wide range of radioisotope-focused products [5] Branding and Operations - The INIS branding will still be utilized for segments focused on high energy sources, bulk radioisotopes, and stable isotopes, while other brands like Radqual and Radvent will operate under the Radnostix umbrella [2] - The management team and commitment to customers and partners will remain unchanged despite the rebranding [2] Product Offerings - Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical products for hyperthyroidism and thyroid cancer [5] - The company also provides contract manufacturing of various drug products and radioisotope API supply for third-party theranostics clients [5] - Additionally, Radnostix produces calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems, as well as industrial calibration standards under the RadQual brand [5] Stock Information - The company's common stock will continue to trade under the ticker symbol "INIS" on the OTCQB marketplace, with potential announcements regarding a new ticker symbol in the future [4]

The FDA approved Vanda's drug Nereus to prevent motion-induced vomiting, opening a potential path into treating nausea linked to GLP-1 weight-loss drugs. ...

Key Takeaways RARE rises 15.5% after finishing its rolling BLA submission to the FDA for DTX401 in GSDIa.DTX401 aims to treat the underlying cause of GSDIa, a rare disorder with no approved drug therapies.RARE's BLA is backed by phase III data showing reduced cornstarch use and improved glucose control.Shares of Ultragenyx Pharmaceutical (RARE) were up 15.5% yesterday following the completion of the rolling submission of a biologics license application (“BLA”) to the FDA seeking approval for its AAV gene th ...

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Johnson & Johnson (JNJ), and emphasizes the importance of using these recommendations in conjunction with other analytical tools like the Zacks Rank for making informed investment decisions [1][5]. Brokerage Recommendations for Johnson & Johnson - Johnson & Johnson has an average brokerage recommendation (ABR) of 1.85, indicating a consensus between Strong Buy and Buy, based on 26 brokerage firms [2]. - Out of the 26 recommendations, 14 are classified as Strong Buy and 2 as Buy, representing 53.9% and 7.7% of total recommendations respectively [2]. Limitations of Brokerage Recommendations - Solely relying on brokerage recommendations may not be advisable, as studies indicate they often fail to guide investors effectively towards stocks with high potential for price appreciation [5]. - Analysts from brokerage firms tend to exhibit a positive bias in their ratings due to vested interests, issuing five "Strong Buy" recommendations for every "Strong Sell" [6][11]. Zacks Rank as an Alternative Indicator - The Zacks Rank, which categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell), is presented as a more reliable indicator of near-term price performance, driven by earnings estimate revisions [8][12]. - Unlike the ABR, the Zacks Rank is timely and reflects the latest earnings estimates, making it a more effective tool for predicting stock price movements [13]. Current Earnings Estimates for Johnson & Johnson - The Zacks Consensus Estimate for Johnson & Johnson's current year earnings has remained stable at $10.87 over the past month, indicating analysts' optimism regarding the company's earnings prospects [14]. - The Zacks Rank for Johnson & Johnson is currently 2 (Buy), influenced by the recent changes in consensus estimates and other related factors [15].

On Wednesday, the U.S. Food and Drug Administration (FDA) accepted Axsome Therapeutics Inc.’s (NASDAQ:AXSM) supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for Alzheimer’s disease agitation.The FDA granted the application Priority Review designation and set a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026.A Priority Review designation means the FDA’s goal is to take action on an application within 6 months, compared to 10 months under ...

Pfizer currently trades at a forward price-to-earnings ratio (P/E) of approximately 8.6x. To understand how affordable this is, you must compare it to the competition. The average company in the pharmaceutical sector trades at a multiple of 15x to 20x earnings. High-growth competitors like Eli Lilly (NYSE: LLY) trade at multiples significantly higher than that.For value investors, the argument for Pfizer is grounded in simple mathematics. The market is currently pricing the company as if its earnings will p ...

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) rose sharply during Wednesday's session after the company announced it intends to file a new drug application in January for AXS-12 after receiving feedback from the FDA. Additionally, the company announced the FDA granted Priority Review to AXS-05 for Alzheimer’s Agitation.Axsome Therapeutics shares surged 16.1% to $172.90 on Wednesday.Here are some other big stocks r ...